Amicus Therapeutics is a biopharmaceutical company that is a part of the New Jersey community. They have recently worked closely with the FDA to approve a new oral medication for Fabry disease, which was a milestone for those living with this disease. That is a part of the work that Amicus Therapeutics does, to better the life’s of others through their hard work and cooperation with other agencies such as the U.S. FDA. On the Amicus Therapeutics website, they state that they put patients first, that science is at the core of their business, and that they work hard to discover treatments for the most devastating diseases.
Amicus Therapeutics portfolio of programs includes a locating treatment for Fabry disease and Epidermolysis Bullosa (EB) and Pompe disease. Amicus Therapeutics strives to deliver significant benefits to patients and to better their lives by coming up with answers to their questions about their difficult diseases that they live with day in and day out. They announced the launch of new drug and is set to be launched later in 2017. This drug that was created by Amicus Therapeutics is backed by NDA and hopefully by the FDA soon. By careful research, they have created this drug to slow the progression of Fabry disease and to lessen the symptoms such as heart disease and kidney failure and to prolong health for those that were unfortunate to be diagnosed.
Amicus Therapeutics has made significant breakthroughs in both slowing progressions and successfully mitigating symptoms of horrible but lesser known diseases. They have a second research facility in San Diego and despite having some funding and partnering setbacks, they have carried out their goal in helping those whose diseases take over every aspect of their lives (Facebook). Amicus Therapeutics were built and stand upon that regime of hard working scientific research to help them dig deeper into different diseases and how to cure people in need.
More about Amicus Therapeutics at https://finance.yahoo.com/quote/FOLD?ltr=1